Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30

Rhea-AI Summary

Renalytix plc (NASDAQ: RNLX) will report its first quarter fiscal year 2023 financial results on November 30, 2022, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the results, business strategy, regulatory processes, and partnerships. Renalytix is a leader in bioprognosis for kidney health, with its flagship product, KidneyIntelX™, receiving Breakthrough Designation from the FDA to improve kidney disease prognosis and management.

Positive

• KidneyIntelX™ received Breakthrough Designation from the FDA.

Negative

• None.

LONDON and SALT LAKE CITY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2023 financial results on Wednesday, November 30, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).

Conference Call Details:
To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

Webcast Registration link: https://edge.media-server.com/mmc/p/88vepbze

About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

For further information, please contact:

Renalytix plc			www.renalytix.com
James McCullough, CEO			Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)			Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)			Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth / Alice Woodings		Mob: 07980 541 893 / 07584 391 303 / 07407 804 654
CapComm Partners
Peter DeNardo		Tel: 415-389-6400 or investors@renalytix.com

FAQ

When will Renalytix report its financial results for Q1 fiscal year 2023?

Renalytix will report its financial results on November 30, 2022.

What time is the Renalytix conference call scheduled for?

The conference call is scheduled for 8:30 a.m. ET on November 30, 2022.

What is KidneyIntelX™ and its significance?

KidneyIntelX™ is Renalytix's lead product designed to improve the prognosis and management of kidney disease; it has received Breakthrough Designation from the FDA.

What topics will be discussed during the Renalytix conference call?

The conference call will cover financial results, business strategy, partnerships, and regulatory processes.